30.3 C
Vientiane
Wednesday, July 9, 2025
spot_img
Home Blog Page 757

NUHS TRIBUTE AWARDS CEREMONY HONOURS EXEMPLARY HEALTHCARE PROFESSIONALS CHAMPIONING THE HEALTH SYSTEM OF THE FUTURE

The National University Health System (NUHS) honours 77 exceptional individuals and four teams driving transformative change in healthcare

SINGAPORE, March 1, 2025 /PRNewswire/ — The National University Health System (NUHS) is at the forefront of transforming healthcare, driving new models of care that extend beyond hospitals into the community. In recognition of outstanding contributions in patient care, research and education, NUHS will honour 77 healthcare professionals and four teams at the NUHS Tribute Awards Ceremony 2025attended by Guest of Honour, Deputy Prime Minister and Minister for Trade and Industry, Mr Gan Kim Yong. 

The NUHS Tribute Awards Ceremony 2025 celebrates excellence in patient care, research and education. Mr Gan Kim Yong, Deputy Prime Minister and Minister for Trade and Industry attended the event as Guest of Honour.
The NUHS Tribute Awards Ceremony 2025 celebrates excellence in patient care, research and education. Mr Gan Kim Yong, Deputy Prime Minister and Minister for Trade and Industry attended the event as Guest of Honour.

This year marks a significant milestone as NUHS introduces the prestigious Emeritus Fellow title, which extends honorary recognition to a wider group of distinguished professionals. In addition, the Master Clinician award category of the NUHS Pinnacle Awards has been expanded to include nurses and allied health professionals, reinforcing NUHS’s commitment to acknowledging excellence across all disciplines and professional groups.

Honouring lifelong contributions to healthcare

The inaugural Emeritus Fellow title is conferred on four outstanding professionals, whose pioneering efforts in nursing, diagnostics and pharmacy have transformed healthcare delivery and education:

  • Dr Emily Ang, Senior Nurse Advisor at Alexandra Hospital (AH) – A key figure in nursing leadership, Dr Ang has served in the NUHS cluster for nearly two decades, from leading oncology nursing at NCIS, to heading the NUS Alice Lee Centre for Nursing Studies (NUS Nursing), as well as serving as Group Chief Nurse of NUHS up till 2022.
  • Mrs Lee Siu Yin nee Yong, Senior Nurse Mentor at AH – A transformational leader in nursing, Mrs Lee’s efforts in advanced practice nursing, education and nursing workforce expansion at the National University Hospital (NUH) have left a lasting impact on Singapore’s healthcare system. Today, she continues to mentor the next generation of nurses at AH.
  • Dr Tyrone Goh, Advisor to the Allied Health Council at NUHS and Chief Executive Officer of the NUH Referral Laboratory at NUH – A pioneering leader in diagnostics and allied health services, Dr Goh has been instrumental in advancing clinical support services and teleradiology in Singapore
  • Mr Wu Tuck Seng, Advisor to the Departments of Pharmacy at NUH and AH – A pharmacy innovator, Mr Wu spearheaded Asia-Pacific’s first inpatient pharmacy automation system and played a pivotal role in shaping Singapore’s pharmacy education and national strategy.

This year, 62 award recipients will receive the NUHS Pinnacle Awards – across the categories of Master Clinician, Outstanding Mentor, Research Excellence, Excellence, Young Achiever and Team – as well as the Distinguished Senior Clinician Awards. Additionally, 16 long-serving clinicians and professionals with exceptional achievements will be conferred the lifetime honorary titles of Emeritus Consultant and Emeritus Fellow[1].

“The outstanding work and contributions by our people and teams enable NUHS to deliver world-class care for our patients today,” said Professor Yeoh Khay Guan, Chief Executive, NUHS. “Likewise, the passion and commitment to excellence embodied by our 17,000-strong healthcare family is the driving force that propels our transformation into the health system of tomorrow.”

Driving change, transforming care

Since its inception in 2020, the NUHS@Home programme has significantly expanded, ramping up virtual bed capacity and clinical pathways, so that more patients can benefit from hospital-level care in the familiar sanctuary of their homes.

To date, NUHS@Home has treated more than 2,900 patients and saved over 17,000 bed days – 9,710 of which were in 2024 alone. In 2024, NUHS@Home expanded its reach to acutely ill patients in two nursing homes. These achievements have earned the NUHS@Home team the NUHS Pinnacle Team Award.

In line with a nationwide initiative to support care beyond acute hospitals, the NUHS@Home programme plans to expand its virtual bed capacity from the current 75 to 100 this year, and to 400 by 2030. New clinical pathways, including for patients post hematopoietic stem cell transplants and post total knee replacements, were launched last year, enabling more patients with different conditions to benefit from the programme.

For Mr Sulaiman, 33, who suffered severe traumatic injuries in a horrific road traffic accident in mid-2024, NUHS@Home provided a crucial lifeline. After nearly two-and-a-half months in NUH, Mr Sulaiman transitioned to the NUHS@Home programme in September 2024.

With the comprehensive support of NUHS@Home, which provided Mr Sulaiman with daily virtual consultations and regular remote vitals checks, he was able to continue recuperating in the comfort of his home.

“Every day, the doctor would check in with me during the video calls to ensure that everything was going smoothly at home,” he recalled. “I was given an emergency contact number and guidance on symptoms to watch for, so that gave me peace of mind.”

Another Team Award recipient that has grown from strength to strength is the NCIS On-The-Go programme, which, since its inception in 2017, has expanded its services from initial blood tests to include 19 different treatments. The community-based cancer treatment programme has established three community clinics, with plans for a fourth clinic in the pipeline, to reduce travelling and wait times for more eligible patients.

Patient visits have multiplied ten-fold since 2017, and the NCIS On-The-Go programme presently decants over 11 per cent of the total cancer treatment workload at National University Cancer Institute, Singapore (NCIS), increasing overall capacity and maintaining comparable safety standards.

Accelerating digital transformation amidst healthcare challenges

With numerous challenges on the horizon – including a rapidly ageing population, pressing manpower shortage and increasing demand for healthcare services – NUHS is accelerating digitalisation and AI adoption to streamline processes and ensure sustainability.

Under the leadership of Dr Alexander Yip, Clinical Director of Alexandra Hospital’s Healthcare Redesign Department and recipient of the Excellence Award, NUHS is pioneering the development of Singapore’s first fully integrated virtual hospital. The Alexandra Virtual Hospital (AVH) integrates connected health devices, advanced video technology, predictive data management and unified communications systems to provide seamless and comprehensive care both within and beyond the hospital’s walls.

As part of the AVH initiative, Dr Yip and team have successfully implemented Smart Wards and a Living Lab to foster innovation in healthcare delivery. These test beds not only enhance patient care and safety, but also revolutionise clinical and nursing workflows, significantly easing the strain on healthcare resources.

Looking to the future, Dr Yip and his team are poised to expand AVH’s capabilities, particularly in remote patient care. This is projected to enhance operational efficiency and reduce the inpatient nursing workforce requirements. This strategic reduction will alleviate current manpower constraints and allow nursing staff to concentrate on more complex and critical tasks, ultimately enhancing patient care and system efficiency.

As NUHS celebrates these exemplary individuals and pioneering initiatives, the awards highlight a shared commitment to advancing healthcare. From digital health innovations to community-based care models, the awardees exemplify the expertise and leadership shaping the future of healthcare. With this drive for innovation, NUHS continues its mission to build an academic health system that is patient-centric, sustainable and future-ready.

About the National University Health System (NUHS)

­The National University Health System (NUHS) aims to transform how illness is prevented and managed by discovering causes of disease, development of more effective treatments through collaborative multidisciplinary research and clinical trials, and creation of better technologies and care delivery systems in partnership with others who share the same values and vision.

Institutions in the NUHS Group include the National University Hospital, Ng Teng Fong General Hospital, Jurong Community Hospital, Alexandra Hospital and the upcoming Tengah General and Community Hospital; three National Specialty Centres – National University Cancer Institute, Singapore (NCIS), National University Heart Centre, Singapore (NUHCS) and National University Centre for Oral Health, Singapore (NUCOHS); the National University Polyclinics (NUP); Jurong Medical Centre; and three NUS health sciences schools–NUS Yong Loo Lin School of Medicine (including the Alice Lee Centre for Nursing Studies), NUS Faculty of Dentistry and NUS Saw Swee Hock School of Public Health.

With member institutions under a common governance structure, NUHS creates synergies for the advancement of health by integrating patient care, health science education and biomedical research. As a Regional Health System, NUHS works closely with health and social care partners across Singapore to develop and implement programmes that contribute to a healthy and engaged population in the Western part of Singapore.

For more information, please visit www.nuhs.edu.sg.

ANNEX

About the NUHS Tribute Awards

The biennial NUHS Tribute Awards honour NUHS healthcare professionals who have made outstanding contributions to patient care, research and education in the academic health system. These prestigious awards recognise individuals and teams who embody the NUHS mission, vision and values, driving excellence in healthcare and shaping the future of medicine.

This year marks a significant milestone with the introduction of the Emeritus Fellow title for a wider group of healthcare professionals. Additionally, the Master Clinician category of the NUHS Pinnacle Awards has been expanded to include nurses and allied health professionals, reflecting NUHS’s commitment to recognise excellence across all disciplines of healthcare.

Now in its fifth edition, the NUHS Tribute Awards 2025 will celebrate the achievements of:

  • 52 Pinnacle Award recipients
  • 10 Distinguished Senior Clinician Award recipients
  • 12 Emeritus Consultants
  • 4 Emeritus Fellows

Award categories

Award

Description

Emeritus Consultant

The NUHS Emeritus Consultant is a lifetime honorary title conferred upon long-serving, esteemed senior clinicians for their distinguished contributions to patient care, education and research, advancing the mission of NUHS.

Emeritus Fellow

The NUHS Emeritus Fellow is a lifetime honorary title conferred upon long-serving, esteemed nurses, allied health professionals, and other healthcare leaders for their distinguished contributions to patient care, education and research, advancing the mission of NUHS.

Master Clinician Award

This award recognises clinicians who have contributed significantly towards elevating the quality of healthcare delivery. They are skilful and compassionate practitioners who are recognised for leadership in their respective areas of specialty.

Outstanding Mentor Award

This award recognises clinicians and academic staff who have displayed professional excellence in medical teaching and mentorship, and contributed significantly to the clinical education of clinicians and clinician scientists.

Research Excellence Award

This award recognises individuals who have undertaken a research study project that has contributed significantly to bridging the gap between knowledge and practice,

resulting in improved standards of care, healthcare outcomes, higher efficiency and more effective patient-centred services.

Excellence Award

This award recognises individuals who have made significant contributions to NUHS’s clinical, research and education missions. Their work has had a major impact, leading to improved standards of care, outstanding health research and exceptional medical education – paving the way for better healthcare outcomes and lasting benefits.

Young Achiever Award

This award recognises young individuals who have excelled in their professional fields, exhibited promising leadership skills, and served as exemplary role models for their peers.

Team Award

This award recognises teams that have successfully implemented clinical quality or practice improvement projects with a strong research-driven approach to knowledge translation, effectively bridging the gap between evidence and practice to enhance patient care and outcomes.

Distinguished Senior Clinician Award

Distinguished Senior Clinicians are recognised as leading experts and key opinion leaders in their professional fields.  They have made distinguished contributions to the medical or dental professions, the Singapore public healthcare sector, and the international community across clinical service, education and research domains.

 

[1] 77 individuals will be honoured in all, as Assistant Prof David Terrence Consigliere is a double award winner with the conferment of Emeritus Consultant and also the Outstanding Mentor Award.

 

Supermicro Expands US Manufacturing Capacity and Development of Industry-Leading Total IT Solutions with Third Campus in Silicon Valley

Supermicro Drives Innovation, Job Creation, and Economic Growth in San Joses Thriving Tech Market

SAN JOSE, Calif., March 1, 2025 /PRNewswire/ — Supermicro, Inc. (NASDAQ: SMCI), a Total IT Solution Provider for AI, Cloud, Storage, and 5G/Edge, is pushing forward with a major expansion, announcing plans for a third campus in Silicon Valley. The first building will be over 300,000 square feet, yet the third campus is expected to be nearly 3 million square feet when completed.  With the mayor’s support, this expansion strengthens Supermicro’s position as an industry leader, accelerating liquid-cooled and Data Center Building Block Solutions® for data centers and customers while creating new jobs and opportunities for local talent. Supermicro is the leading IT manufacturer headquartered in the USA.

Supermicro's San Jose Expansion
Supermicro’s San Jose Expansion

“We are thrilled to grow our footprint in Silicon Valley,” said Charles Liang, president and CEO of Supermicro. “As AI factories become more prevalent, liquid-cooled data centers are critical to meet these increasing customer demands. We anticipate that up to 30% of new data centers will adopt liquid cooling solutions. Today, Supermicro can deliver 5,000 air-cooled or 2,000 liquid-cooled racks per month to support substantial orders. This expansion is a major step forward in our vision for innovation, investment in workforce, quality, Time-to-Deployment (TTD), Time-to-Online (TTO) service, and technological advancement.”

Learn more about Supermicro’s Building Block liquid cooling solutions here.

“We’re proud to be home to Supermicro, one of the fastest growing and most innovative companies powering the AI revolution with nearly 3,000 local employees and growing,” said San Jose Mayor Matt Mahan. “With this planned expansion, Supermicro is helping San Jose redefine what ‘Made in America’ looks like and creating high paying new jobs to fuel our economy.”

The new development is expected to generate hundreds of new jobs across multiple sectors, including engineering, production, and corporate roles. Supermicro is developing building block liquid-cooled solutions for AI factories and the HPC market, that will help data centers run more efficiently by reducing carbon footprint and saving on operational cost through lower electricity usage over time.  

“PG&E is excited to support Supermicro’s continued expansion in Silicon Valley,” said Teresa Alvarado, vice president for PG&E’s South Bay and Central Coast Region. “Through our ongoing investments in infrastructure and clean energy, PG&E is poised to provide reliable and sustainable power to meet the growing needs of the tech sector.”

Supermicro continues to work closely with data center operators to match the right server technology to the demanding workloads. With its strong commitment to advancing technology, empowering talent, and driving long-term economic growth, construction at the new site is set to begin in 2025.

About Super Micro Computer, Inc.

Supermicro (NASDAQ: SMCI) is a global leader in Application-Optimized Total IT Solutions. Founded and operating in San Jose, California, Supermicro is committed to delivering first-to-market innovation for Enterprise, Cloud, AI, and 5G Telco/Edge IT Infrastructure. We are a Total IT Solutions manufacturer with server, AI, storage, IoT, switch systems, software, and support services. Supermicro’s motherboard, power, and chassis design expertise further enables our development and production, enabling next-generation innovation from cloud to edge for our global customers. Our products are designed and manufactured in-house (in the US, Asia, and the Netherlands), leveraging global operations for scale and efficiency and optimized to improve TCO and reduce environmental impact (Green Computing). The award-winning portfolio of Server Building Block Solutions® allows customers to optimize for their exact workload and application by selecting from a broad family of systems built from our flexible and reusable building blocks that support a comprehensive set of form factors, processors, memory, GPUs, storage, networking, power, and cooling solutions (air-conditioned, free air cooling or liquid cooling).

Supermicro, Server Building Block Solutions, and We Keep IT Green are trademarks and/or registered trademarks of Super Micro Computer, Inc.

All other brands, names, and trademarks are the property of their respective owners.

 

AIIB Report Urges Infrastructure Development to Prioritize Health, Climate and Nature to Save Lives and Protect Planet

CAPE TOWN, South Africa, March 1, 2025 /PRNewswire/ — Amid accelerating climate change and an increasingly challenged global health system, a new report from the Asian Infrastructure Investment Bank (AIIB) redefines how we think of, invest in, and build systems to safeguard human health. Without novel approaches, human-induced changes to climate nature and biodiversity threaten to undermine decades of progress in global health.

“Investment in human health is an investment in our future—stronger communities, resilient livelihoods, and lasting prosperity,” said AIIB President Jin Liqun. “Planetary and human health are inseparable. At AIIB, we are committed to ensuring infrastructure acts as a catalyst for better health outcomes and environmental resilience. By scaling up investment in infrastructure for planetary health, we can break the cycle of environmental degradation and declining health.”

AIIB launched the 2025 Asian Infrastructure Finance Report, titled “Infrastructure for Planetary Health,” at the fifth edition of the Finance in Common (FiCS) Summit in Cape Town, South Africa.

Drawing on data and case studies from across the world, the report covers examples of how infrastructure development can improve public health outcomes. These include measures to control air pollution and mitigate the impact of water- and vector- borne diseases, such as malaria and dengue, in developing economies through infrastructure investment.

AIIB Chief Economist Erik Berglof said the concept of infrastructure for planetary health arrives at a pivotal moment: “Changes to the climate, nature and biodiversity are having a catastrophic impact on human health and well-being. Currently a quarter of global deaths a year can be attributed to avoidable environmental factors. Infrastructure for planetary health, for the first time, considers the tremendous health co-benefits of sustainable infrastructure development.”

The report outlines three key investment themes financiers can enact to achieve this concept:

  • Investing in accessible, green and resilient healthcare infrastructure. Increasing the accessibility and climate resilience of healthcare would ensure the maintenance of effective operations during disasters and extreme weather events and adapt to changing disease patterns due to climate change and nature degradation.
  • Scaling up green infrastructure and opting for ‘health-in-infrastructure’ approach. Reducing reliance on fossil fuels, backed by renewables and adequate transmission, reduces population exposure to air pollution.
  • Investing in nature-based solutions. Nature-based approaches in infrastructure or investing directly in nature deliver multiple benefits to health and well-being. Well-functioning ecosystems provide clean air and water, food, medicines and protection against extreme weather events.

“The global health landscape has evolved, and so must our response. All infrastructure – whether energy, transport, water or digital – should be guided by health impact. Multilateral development banks must realize their convening power to support investors to identify and mobilize the needed financing for new infrastructure for planetary health,” Berglof added.

Incorporating health, climate mitigation and adaption, nature-based solutions, and conservation into investments is already a key priority at the Bank and forms a key part of its Climate Action Plan (CAP) and inaugural health strategy, which was launched in December 2024. As part of the CAP, AIIB signalled its intention to focus on solutions that simultaneously mitigate climate change, build resilience, enhance adaptation and offer co-benefits for biodiversity and nature conservation. While the health strategy provides a roadmap to address health challenges across members and underscores AIIB’s commitment to social development and inclusion by enabling it to contribute to improved health outcomes in Asia and beyond. AIIB has financed 22 health projects with an approved value of USD4.87 billion.

 

MAIRE AND KAZAKH-BRITISH TECHNICAL UNIVERSITY SIGN MEMORANDUM ON THE DEVELOPMENT OF INTERNATIONAL COOPERATION IN SCIENCE AND EDUCATION TO FOSTER COMPETENCES FOR THE ENERGY TRANSITION

MILAN, March 1, 2025 /PRNewswire/ — MAIRE has signed a Memorandum of Understanding with Kazakh-British Technical University (KBTU) to cooperate on further enhancing international collaboration in research and education, fostering innovation and development to support the energy transition.

This three-year agreement aims to promote a range of initiatives, including guest lectures by MAIRE’s experts for KBTU students, internship opportunities at the company’s facilities, sponsorship awards and research grants for outstanding KBTU students, and support for KBTU graduates in job placements and career development. As part of the agreement, KBTU is launching a new educational program focused on the energy transition, as well as modular courses for master’s students. The program aims to train highly qualified specialists with expertise in sustainable energy and innovative technologies. Additionally, the partnership includes joint supervision of master’s theses.

The agreement was signed by Prof. Maratbek T. Gabdullin, Rector of KBTU, and Niccolò Heilpern, Central Asia, Caspian and Turkey Region Vice President, MAIRE group, at the presence of Mr. Edoardo Crisafulli, cultural attaché of the Italian Embassy in Kazakhstan and Director of the Italian Institute of Culture in Almaty, Mr Martino Castellani, Director of ITA/ICE. 

This MoU reinforces the Group’s belief that partnerships with universities are crucial to developing the technical and engineering skills required today, enabling to face the challenges of the energy transition with a new perspective. This is what clearly emerges from the study “Climate goals: winning the challenge of climate goals through the creation of skills and competences worldwide. Addendum 1: focus AzerbaijanKazakhstan” carried out by the Fondazione MAIRE and presented during COP29 in Baku. The energy transition process in the Country requires a substantial upskilling of the workforce acknowledging the need for additional training in energy transition-related topics to position itself advantageously in the emerging green economy landscape.

KBTU Rector (Chairman of the Board) Maratbek Gabdullin emphasized:
“This memorandum opens new opportunities for KBTU students and faculty. Collaboration with MAIRE will provide our students access to cutting-edge knowledge, innovative technologies, and real-world experience in a leading international company. We are confident that this initiative will contribute to the training of highly qualified specialists in high demand during the global energy transition.”

Niccolò Heilpern, Central Asia, Caspian and Turkey Region VP of MAIRE, commented: “We are eager to start this cooperation with KBTU aimed at fostering innovation while sharing our know-how to support academic excellence in line with our In-Country Value strategy for Kazakhstan. This collaboration will provide valuable opportunities for KBTU students and contribute to develop skills and competences in the regional industry scenario”.

 

BK8 News Is The New Title Sponsor Of Gresini Racing MotoGP: Let’s Get Started


BURIRAM, THAILAND – Media OutReach Newswire – 1 March 2025 – Starting Today, the Gresini Racing MotoGP team will officially be known as BK8 Gresini Racing MotoGP. This marks the latest major announcement – just days before the highly anticipated start to the 2025 season at the Buriram International Circuit in Thailand.

BK8 NEWS, a sports news and entertainment platform providing up-to-date sports coverage and fan engagement worldwide, will become the Title Sponsor of the Faenza-based team for the 2025 and 2026 seasons. Besides naming rights, BK8 NEWS will enjoy prominent visibility on the Desmosedici GP24, as well as on the racing suits of Alex Marquez and Fermin Aldeguer. Additionally, the BK8 NEWS brand will feature on team uniforms, garage panels, and transport vehicles.

This sponsorship marks the largest partnership to date for BK8 NEWS and aims to offer a powerful marketing tool to engage fans on a global scale. It is designed to support brand growth by leveraging the massive audience of MotoGP, particularly in key markets where the company operates, maximizing visibility and fan engagement.

MICHAEL GATT – MANAGING DIRECTOR, BK8 NEWS
“We’re excited to team up with Gresini Racing, marking a significant milestone in our strategic growth. This collaboration reflects our commitment to performance, precision, and excellence. By teaming up with a team that pushes the boundaries of motorsport, we’re establishing our presence in one of the world’s most iconic motorsport events. Together, we’ll fuel Gresini Racing’s success, bringing fans closer to the action with exclusive insights and behind-the-scenes access.”

CARLO MERLINI – COMMERCIAL & MARKETING DIRECTOR, GRESINI RACING

“I am thrilled to announce the signing of a title sponsorship agreement for the Gresini Racing MotoGP Team. Adrenaline, speed, and excitement make MotoGP an incredibly powerful marketing platform, offering brands unparalleled global visibility… and Gresini Racing stands among the best organisations in the sport. It’s no surprise that a major brand like BK8 NEWS has chosen the exceptional Gresini – MotoGP combination as its flagship project to achieve its goals. I want to extend my gratitude to everyone at BK8 NEWS for their dedication and commitment over the past few weeks in making this project a reality… I truly can’t wait to hit the track in our new colours and kick off the BK8 NEWS Gresini MotoGP Team in the best way possible.”

SALAUDDIN SINNAKANDU – CHIEF EXECUTIVE OFFICER, OUTLAST SPORTS & ENTERTAINMENT
“We are pleased to have facilitated this partnership, bringing together two influential brands with a shared vision. It’s exciting to see this collaboration come to life, and I’m confident it will open up new opportunities for both brands within the world of motorsport.”

BK8 NEWS operates in the fields of sports news and entertainment. It is a sports information and entertainment site that provides up to date sports news and enables engagement with the sports fans all around the world.

Hashtag: #motogp #gresini #bk8news #gresiniracing #bk8newsgresiniracingmotogp #buriram

The issuer is solely responsible for the content of this announcement.

China CITIC Bank International and Hong Kong Airlines to launch co-branded Mastercard® card

Strengthening credit card product portfolio Travel offers and rewards to drive credit card spending


HONG KONG SAR – Media OutReach Newswire – 28 February 2025 – China CITIC Bank International Limited (“CNCBI”) and Hong Kong Airlines (“HKA”) today announce the launch of the China CITIC Bank International Hong Kong Airlines co-branded Mastercard® card, providing customers exceptional travel experiences and rewards, further enhancing the CNCBI credit card product portfolio while helping to driving credit card spending.

(from left to right): Ms Helena Chen, Managing Director, Hong Kong & Macau, Mastercard; Ms Wendy Yuen, Head of Personal & Business Banking Group, China CITIC Bank International Limited; and Mr Yan Bo, Chairman, Hong Kong Airlines announce the launch of the China CITIC Bank International Hong Kong Airlines Mastercard® card.
(from left to right): Ms Helena Chen, Managing Director, Hong Kong & Macau, Mastercard; Ms Wendy Yuen, Head of Personal & Business Banking Group, China CITIC Bank International Limited; and Mr Yan Bo, Chairman, Hong Kong Airlines announce the launch of the China CITIC Bank International Hong Kong Airlines Mastercard® card.

With a view to satisfying customers’ needs for travel and credit card spending as global tourism recovers, CNCBI and HKA have joined forces to launch the China CITIC Bank International Hong Kong Airlines co-branded Mastercard® card with myriad rewards, including welcome complimentary air ticket1, bonus spending rewards and exclusive travel privileges. Customers may take advantage of a flexible and more favourable points reward system and earn points quicker for discounted air tickets redemption. Other rewards include complimentary travel insurance2, airport lounge access3 and a range of other privileges that allow customers to reap rewards for their spending when travelling abroad.

Ms Wendy Yuen, Head of Personal and Business Banking Group, CNCBI, said, “Tourism started to pick up its pace since the second half of 2023 which fuelled the overseas travelling boom for Hong Kong people. Based on 2024 figures, overseas spending has accounted for more than 20% of the total value of credit card transactions at CNCBI. Against this backdrop, the Bank and HKA are rolling out this new co-branded credit card with the objectives to offer travel enthusiasts more appealing spending & travel rewards. At the same time, it enriches the credit card portfolio of CNCBI.”

Mr. Yan Bo, Chairman of Hong Kong Airlines, stated, “We are delighted to launch a co-branded credit card in partnership with CNCBI, marking a significant milestone in Hong Kong Airlines’ service innovation. This collaboration not only offers cardholders an array of travel privileges including points redemption for air tickets, priority boarding, and airport lounge access, but also establishes a new standard for the integration of aviation and financial services. As an airline deeply rooted in Hong Kong, we are committed to delivering a high-quality travel experience for our passengers and driving industry innovation. We are confident that this partnership will invigorate travel and consumption for the people of Hong Kong.”

Exciting rewards for travelling and spending

China CITIC Bank International Hong Kong Airlines Mastercard® card welcome offers and exclusive rewards include:

– Welcome offer: Earn up to 104,000 Fortune Wings Club (FWC) points (can redeem four sets of round-trip ticket to Okinawa / Shanghai or other destinations)4

  • Earn 26,000 FWC points with spending of HK$25,000 within the first five months from card issuance1
  • Redeem 26,000 FWC points with HK$800 for every additional spending of HK$15,000 from card issuance (Maximum 3 times) 1.
  • 26,000 FWC points can redeem one set of round-trip ticket to Okinawa, Shanghai or other destinations4

Spending rewards: As low as HK$2 = 1 FWC point5

Annual promotion: Cardholders have two opportunities annually to redeem HKA tickets to selected destinations at a 50% off using FWC points

Business class upgrade offer: 50% off FWC points

Aside from flight rewards, CNCBI HKA Mastercard® cardholders may also enjoy an array of exclusive travel privileges including free travel insurance2, HKA airport lounge service3, exclusive check-in counters, priority boarding and baggage handling, in-flight duty-free discounts, as well as additional FWC points when purchasing tickets from the HKA official website and mobile app.

Offers are subject to terms and conditions.

To borrow or not to borrow? Borrow only if you can repay!

Remarks:

1. The promotion is valid until 2 July 2025. It is applicable to applicants who do not hold any CNCBI Credit Card principal card in the past 12 months from the approval month of current applications.
2. Offers are provided by Mastercard® and are subject to relevant terms and conditions. Please visit the Mastercard® website for details.
3. The promotion is valid until 31 December 2025. Two Hong Kong Airlines lounge vouchers are awarded upon any spending.
4. The points redemption standard is based on Hong Kong Airlines’ reward economy class (R) ticket redemption standard as of January 1, 2025, and is subject to Hong Kong Airlines’ latest announcements and may change from time to time. Customers are responsible for all applicable taxes, airport construction fees or government fees, fuel surcharges, security fees, insurance fees, and any fees charged by any authorized entity in connection with the use of points-redeemed tickets.
5. Hong Kong Airlines spending: HK$2 = 1 FWC point. Overseas and online spending: HK$4 = 1 FWC point. Local retail spending: HK$6 = 1 FWC point.

Hashtag: #CNCBI #HKA

The issuer is solely responsible for the content of this announcement.

China CITIC Bank International Limited

China CITIC Bank International Limited (“CNCBI”), a major offshore platform of commercial banking business of the CITIC Group, is 75%-owned by CITIC International Financial Holdings Limited (“CIFH”), which in turn is a wholly-owned subsidiary of China CITIC Bank Corporation Limited (“CNCB”).

CNCBI’s footprint in Greater China includes 24 branches and two business banking centres in Hong Kong, as well as presence in Beijing, Shanghai, Shenzhen and Macau, and overseas branches in New York, Los Angeles and Singapore.

Across a century, CBCBI has grown together with its employees, customers and partners since 1922 and will continue to move towards its vision of “Agile. Professional. Simple.” in adherence to the 4C (Culture, Customer, Collaboration, Cyberspace) core values while driving actively its missions to “create value for customers, seek happiness for employees, make profit for shareholders, perform responsibility for society”.

More information about China CITIC Bank International can be found on its website at .

Hong Kong Airlines

Established in 2006, Hong Kong Airlines is a full-service airline firmly rooted in Hong Kong. The airline flies to over 30 destinations across the Asia Pacific and North America, and currently maintains interline and codeshares with multiple airline partners and ferry service providers. Hong Kong Airlines operates an all-Airbus fleet. It has been awarded the internationally acclaimed four-star rating from Skytrax since 2011. For more information, please visit or our social media channels on and .

QMMM Holdings Limited Announces to receive Nasdaq Minimum Bid Price Deficiency Letter

HONG KONG, Feb. 28, 2025 /PRNewswire/ — QMMM Holdings Limited (Nasdaq: QMMM) (the “Company” or “QMMM Holdings”), a digital media advertising, virtual avatar & virtual apparel technology service provider in Hong Kong, today announced that on February 26, 2025, the Company received a letter from the Listing Qualifications staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that based on the closing bid price of the Company for the period from January 8, 2025 to February 25, 2025, the Company no longer meets the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5550(a)(2), to maintain a minimum bid price of $1 per share.

Nasdaq has provided the Company with an 180 calendar days compliance period, or until August 25, 2025, in which to regain compliance with Nasdaq continued listing requirement. In the event that the Company does not regain compliance in the compliance period, the Company may be eligible for an additional 180 calendar days, should the Company meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and is able to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. However, if it appears that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that the Company’s securities will be subject to delisting.

The Company is currently evaluating options to regain compliance and intends to timely regain compliance with Nasdaq’s continued listing requirement. Although the Company will use all reasonable efforts to achieve compliance with Rule 5550(a)(2), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq continued listing requirement. 

About QMMM Holdings Limited

QMMM Holdings is an award-winning digital advertising and marketing production services company.

More information about the Company can be found at: https://www.qmmm.io/ 

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “potential,” “continue” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC, which are available for review at www.sec.gov.

For more information, please contact:

QMMM Holdings Limited
Phone: +852 3549 6889
Email: info@qmmm.io

Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT001, a Novel Multi-Targeting, Half-Life Extended Bispecific Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Skin Diseases

Preclinical data with BBT001 demonstrate its best-in-disease potential for improved efficacy and dosing convenience compared to approved biologics in atopic dermatitis

Interim safety and pharmacokinetic data from healthy volunteers anticipated in 2H 2025

BOSTON, Feb. 28, 2025 /PRNewswire/ — Bambusa Therapeutics, Inc. (Bambusa), a clinical-stage biotechnology company developing novel biologics for inflammatory and immunological diseases, today announced the initiation of dosing in healthy volunteers (HV) in its first clinical trial for BBT001, a novel, multi-targeting, half-life extended bispecific antibody, which is being developed initially as a treatment for atopic dermatitis (AD).

“The early initiation of the BBT001 Phase 1 clinical trial is a significant milestone for Bambusa as we continue to execute with excellence,” said Shanshan Xu, M.D., Ph.D., Founder and Chief Executive Officer of Bambusa Therapeutics. “BBT001 represents a potential breakthrough in atopic dermatitis treatment by leveraging innovative antibody engineering to engage multiple, clinically validated, non-overlapping mechanisms of action. Our goal is to deliver faster onset of symptom relief, superior efficacy, and improved dosing convenience that could ultimately redefine the standard of care for AD patients.”

About the BBT001-001 Clinical Trial

The Phase 1 clinical trial (BBT001-001; NCT06808477) is a randomized, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study evaluating BBT001 in healthy volunteers and adults with moderate to severe atopic dermatitis. The trial will assess the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics, and preliminary clinical activity of BBT001 and is expected to enroll approximately 98 participants across multiple cohorts. Interim safety and pharmacokinetic data are anticipated in the second half of 2025.

About BBT001 and Bambusa’s pipeline

BBT001 is a novel half-life extended bispecific antibody. Preclinical data with BBT001 demonstrate its best-in-disease potential, offering enhanced efficacy and improved dosing convenience compared to approved biologics in atopic dermatitis.

Beyond BBT001, Bambusa is advancing BBT002, a bispecific antibody designed as a “platform in a molecule” with broad applications across respiratory, dermatology, and gastroenterology indications. The company’s additional pipeline candidates, BBT003 and BBT004, are also being developed for inflammatory bowel disease and rheumatological conditions, each with best-in-disease potential.

About Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory skin condition characterized by intense itching, dry skin, and recurrent eczematous lesions. It affects approximately 16.5 million adults in the United States alone and can have a significant impact on quality of life.[1] Despite recent therapeutic advances, including targeted biologics, a significant portion of patients continue to experience inadequate disease control, underscoring the need for novel treatment approaches.

About Bambusa Therapeutics

Bambusa Therapeutics is a clinical-stage biotechnology company specializing in developing transformative inflammatory and immunological therapeutics. Based in the vibrant Boston Seaport area, Bambusa’s mission is to advance the field of immunology with cutting-edge solutions. For more information, visit www.bambusatx.com.

[1] https://aafa.org/wp-content/uploads/2022/08/Atopic-Dermatitis-in-America-Study-Overview.pdf